News

New once-a-month drug could treat diabetes and obesity, scientists say
New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...
STAT11h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Devdiscourse9h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Healio9h
Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss
Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...
New Data Shows Just How Powerful the Next Weight-Loss Drugs May Be
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...